ArticlePolymers2026
Nanoengineered Chitosan-Genipin Coating of Yeast-Derived Biopolymer Microcapsules for Theranostic Applications.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The development of effective and trackable drug delivery systems remains a major challenge in anticancer therapy. In this study, we designed novel polysaccharide-based theranostic carriers using a yeast-shell (YC) framework, providing a biocompatible platform for intracellular drug delivery. For the first time, a chitosan-genipin bioconjugate was synthesized via a solvent-free, green mechanochemical method and applied as an outer coating to microcarriers encapsulating the anticancer drug 5-fluorouracil (5-FU) and the fluorescent dye phenosafranin. The resulting system enabled simultaneous fluorescence tracking and the controlled release of the chemotherapeutic agent. In vitro evaluation using the MDA-MB-231 triple-negative breast cancer cell line demonstrated that 5-FU retained its antiproliferative activity, while the carriers facilitate sustained intracellular delivery. These findings highlight the potential of YC-based polysaccharide carriers, surface- modified with chitosan-genipin to enhance hydrophilicity, as a versatile platform for anticancer therapy, combining biocompatibility, traceability, and controlled drug release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.